Teewinot has assembled a veteran management team with demonstrated success in leadership, growth, pharmaceutical development, marketing, and aftermarket support.
Management has organized a team of highly experienced scientists, business people, attorneys and other support personnel who are carefully aligning the intellectual property strategy with business goals and scientific developments. All scientific developments are carefully screened to determine whether they support Teewinot’s business goals and should be best protected as a trade secret or through the patent process. Freedom to bring new products and processes to market is carefully evaluated on an ongoing basis. The intellectual property strategy is designed to enhance Teewinot’s value by providing market exclusivity, freedom-to-operate, and revenue generating opportunities through licensing and sale of assets.
Jeffrey M. Korentur
CEO, President and Director
Mr. Korentur, the CEO, President and Director of Teewinot, is also on the Board of Directors and a co-founder of the company.
With more than 25 years of experience in positions of leadership in military and private sector roles, Mr. Korentur has repeatedly demonstrated the ability to successfully guide teams and achieve mission priorities.
During his career in the US Army, Mr. Korentur’s interests, aptitudes and capabilities provided the opportunity to serve in a variety of diverse roles. Mr. Korentur performed with distinction as a helicopter pilot, linguist, and counterintelligence special agent through multiple domestic and overseas tours of duty.
After completing military service, Mr. Korentur brought his acquired skills to the private sector by leading and managing teams in the development of terrestrial and space-based security and cryptographic systems for voice and data networks. Specific key roles held were deputy to the Chief Network Security Engineer at the Defense Information Systems Agency and Security Audit Team Lead for a classified satellite network. Immediately prior to joining Teewinot, Mr. Korentur was president of KKAD Holdings, a multiple family office focused on investment and management of its portfolio.
Mr. Korentur volunteers his time with Southeast Honor Flight and the American Association of Caregiving Youth. An avid ice hockey fan, Mr. Korentur is certified by USA Hockey as a level IV coach, and has volunteered countless hours coaching local and traveling hockey teams. Mr. Korentur earned a MS in Computer Information Systems from the University of Phoenix during his time in service, and a B.A. in Psychology from the State University of New York at Albany.
Richard Peet, JD, Ph.D.
Executive Vice President
Chief Intellectual Property Counsel
Dr. Peet has more than 30 years’ experience in cross-functional scientific, legal, and business leadership roles spanning research operations, intellectual property strategy, and business development in the life sciences industry. He is an entrepreneurial-minded scientist, lawyer, and business leader with material involvement in multiple successful investor exits. Most recently he co-founded Blue Prairie Brands, LLC which produces a proprietary prebiotic-containing flour made from the chicory plant.
Prior to joining Teewinot Life Sciences Corporation Dr. Peet was a partner at the Am Law 100 law firm Foley & Lardner, LLP where he represented life science companies on patent litigation and procurement matters. He was Chair of the firm’s Chemistry and Biotechnology Practice Group and International Business Team. After 23 years at Foley, Dr. Peet retired from the law firm to join Teewinot’s management team. Prior to joining Foley, Dr. Peet was a research scientist at Sandoz Crop Protection and the Vrije Universteit in Amsterdam, The Netherlands.
Dr. Peet has authorship on numerous peer-reviewed scientific publications as well as articles and a book on intellectual property law issues. He served as an adjunct professor in the George Mason University School of Business for ten years. He is a co-inventor on numerous patents and patent applications.
Dr. Peet obtained his Ph.D. from University of California, Berkeley in the field of molecular biology, received his law degree from the Catholic University, and earned his B.S. from Haverford College.
Dr. Peet serves on the Board of Teewinot subsidiary Full Spectrum Laboratories, Ltd.
Bryan K. Brink
Vice President of Finance
Bryan Brink currently serves as Vice President, Finance for Teewinot and its subsidiary companies. In this position, Mr. Brink manages corporate finance, international banking operations and serves as the internal manager of all audit functions, including the relationship with Ernst & Young.
Prior to joining the Company, he served as the Managing Partner for Grand Teton Investment Group (GTIG) since June of 2008. GTIG owns and operates a number of high-end pubs throughout the State of Florida. Mr. Brink started and grew the company to over five locations producing over $8 million in annual revenue.
Mr. Brink earned his BSBA in finance from the University of Florida. He also earned his MA in Education from the University of South Florida, and earned a second MA in Educational Leadership from Nova Southeastern University. He is married and has five children.
Chief Science Officer
Mr. Sarna is the Chief Science Officer of Teewinot and President of Teewinot’s wholly-owned Canadian subsidiary, CMHB. Mr. Sarna has developed novel analytical methodologies for a wide variety of analytes, including pesticides and pesticide breakdown products, dioxins, dibenzofurans, PCBs, PAHs, chlorinated paraffins and volatile organics using GC, GC-MS and HPLC, and is considered an industry expert in the field of analytical methods development.
Mr. Sarna’s professional career includes a position as a Visiting Research Scientist at the Central Research/Physics Laboratories of Ciba-Geigy (now Novartis AG) in Basel, Switzerland where he investigated the application of chromatographic techniques to the measurement of dioxin vapor pressures for mathematical modelling. In 1993, Mr. Sarna co-founded Websar Laboratories with Dr. G. R. Barrie Webster, and joined the company full-time in 1998 as Vice President of Operations. The company focused on providing consulting and analytical services to both the environmental and the agricultural sectors. In 1998, the laboratory became involved in the testing of industrial hemp for compliance with Health Canada regulations and, at one point, was the preeminent laboratory for industrial hemp analysis in Canada. Industrial hemp testing continued to be offered until the laboratory ceased operation in 2009.
In 2001, Websar Laboratories attracted private venture capital investment for an in-house research project to develop proof of concept for production of a generic pharmaceutical from industrial hemp. The project eventually resulted in $4.8 million dollars of direct investment in Websar Laboratories, and an estimated $4 million dollars of additional funding from a pharmaceutical industry partner, to develop the Drug Master File, conduct clinical trials and successfully file an ANDA for generic dronabinol at the close of 2006. During this period, Len oversaw the company’s reorganization into a pharmaceutical R&D company and was the “point-person” for Websar Laboratories in its dealings with contract manufacturers and regulatory agencies. He was also tasked with identifying new plant-based pharmaceutical product opportunities for future development. In February 2012, Mr. Sarna joined CMH Biotechnologies, Inc. as Vice President and Director of Research, to oversee the establishment of CMH Biotechnologies’ laboratory facilities in Steinbach, Manitoba and to manage its operation.
Mr. Sarna holds a Bachelor of Science Degree (Chemistry) from the University of Winnipeg, and is currently completing the Prairie Horticulture Certificate program through the School of Agriculture at the University of Manitoba. He is a member of the American Association for the Advancement of Science, the American Chemical Society and the American Botanical Council. He has authored/co-authored some 90 research publications, book chapters and conference presentations in chromatographic applications to environmental chemistry and has 8 patent applications in cannabinoid chemistry, three of which have been granted.